Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Trends Parasitol. 2020 Sep;36(9):735-744. doi: 10.1016/j.pt.2020.05.013. Epub 2020 Jun 22.
Artemisinin and its derivatives (ART) are crucial first-line antimalarial drugs that rapidly clear parasitemia, but recrudescences of the infection frequently follow ART monotherapy. For this reason, ART must be used in combination with one or more partner drugs that ensure complete cure. The ability of malaria parasites to survive ART monotherapy may relate to an innate growth bistability phenomenon whereby a fraction of the drug-exposed population enters into metabolic quiescence (dormancy) as persister forms. Characterization of the events that underlie entry and waking from persistence may lead to lasting breakthroughs in malaria chemotherapy that can prevent recrudescences and protect the future of ART-based combination therapies.
青蒿素及其衍生物（ART）是治疗疟疾的关键一线药物，能迅速清除寄生虫血症，但 ART 单药治疗后经常会出现复发。因此，ART 必须与一种或多种确保完全治愈的联合药物联合使用。疟原虫能够在 ART 单药治疗中存活，这可能与内在的生长双稳态现象有关，即一部分暴露于药物的人群进入代谢静止（休眠）状态，成为持久性寄生虫。阐明导致进入休眠和从休眠中苏醒的事件，可能会为疟疾化学疗法带来持久的突破，从而防止复发，并保护基于 ART 的联合疗法的未来。
